Canaccord Genuity its maintaining its Hold rating and $45 price target on Teva Pharmaceutical (NYSE: TEVA) following Q2 results issued ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE